^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Lung Adenocarcinoma
    Drug:Lumakras (sotorasib) (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    LUMAKRAS® (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER

    Excerpt:
    Amgen...announced that LUMAKRAS® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC) that has progressed after systemic anticancer therapy.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

    Excerpt:
    ...Biomarker eligibility for S1900E is based on the identification of a KRAS^G12C mutation...
    Trial ID:
    ECOG-ACRIN LUNG-MAP SUB-STUDY
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Discov Oncol
    Title:

    AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research

    Published date:
    06/07/2023
    Excerpt:
    This study explored whether the AMG-510 and cisplatin combination increases the anti-tumor effect in lung adenocarcinoma with the mutation of Kirsten rat sarcoma viral oncogene (KRAS) G12C….The anticancer effect of the drug combination was confirmed to be better than monotherapy in vitro and in vivo.
    Secondary therapy:
    cisplatin
    DOI:
    10.1007/s12672-023-00698-z.